Dr. Wilder, an internationally recognized rheumatologist/immunologist, has more than 30 years of research experience in the autoimmune and inflammatory diseases. Prior to joining MacroGenics, Dr. Wilder served as the Vice President of Clinical Development at MedImmune, Inc., a publicly-traded biotech company which, like MacroGenics, focuses its research efforts on infectious diseases, cancer and autoimmune diseases. Before moving to industry, Dr. Wilder was Chief of the Inflammatory Joint Diseases Program at the National Institutes of Health (NIH), capping a 25-year career with the institution. Dr. Wilder obtained his M.D. and Ph.D. from the University of California, Los Angeles. He completed an internal medicine residency at the University of California San Diego before joining the NIH. He is board certified in both internal medicine and rheumatology and is the author of more than 250 publications.